United States Molecular Diagnostics Market Analysis

The United States Molecular Diagnostics Market was US$7.98 billion in 2023 and will reach US$14.01 billion by 2032, with a CAGR of 6.45% from 2024 to 2032.

United States Molecular Diagnostics Market Outlooks

Molecular diagnostics is a cutting-edge field of medical science that uses advanced techniques to analyze biological markers in the genetic code (DNA) and proteins. This approach allows for detecting and measuring specific genetic sequences and molecules associated with various diseases and health conditions. By examining these molecular markers, healthcare professionals can more precisely identify pathogens, assess disease risk, diagnose conditions, and predict treatment outcomes than traditional diagnostic methods.

Request a free sample copy of the report:  https://www.renub.com/united-states-usa-molecular-diagnostics-market-test-volume-forecast-and-companies-35-p.php

In the United States, molecular diagnostics has a wide range of applications across healthcare. It’s extensively used in infectious disease testing, enabling rapid and accurate identification of pathogens like viruses, bacteria, and fungi. This technology has been crucial in managing the COVID-19 pandemic. In oncology, molecular diagnostics helps in cancer screening, diagnosis, and treatment selection by identifying specific genetic mutations. It’s also valuable in prenatal testing, pharmacogenomics (studying how genes affect drug response), and monitoring chronic diseases. As personalized medicine gains traction, molecular diagnostics is becoming increasingly crucial in tailoring treatments to individual patients based on their genetic profiles.

Growth Drivers in the United States Molecular Diagnostics Market

Increasing prevalence of infectious diseases and cancer

The rising incidence of infectious diseases and cancer in the United States is a significant driver for the molecular diagnostics market. As these conditions become more prevalent, there’s a growing need for accurate, rapid, and sensitive diagnostic tools. Molecular diagnostics offers superior detection capabilities for pathogens and genetic markers associated with various cancers. The COVID-19 pandemic has further highlighted the importance of molecular testing in disease management and containment. The increasing rates of antibiotic-resistant infections necessitate more precise diagnostic methods to guide appropriate treatment. In oncology, molecular diagnostics is crucial in the early detection, staging, and monitoring of various cancers. As the burden of these diseases continues to grow, the demand for molecular diagnostic tests is expected to increase, driving market expansion.

Advancements in technology and automation

Technological innovations are revolutionizing molecular diagnostics, making tests faster, more accurate, and more cost-effective. Next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies are becoming more sophisticated, allowing for the simultaneous analysis of multiple biomarkers. Integrating artificial intelligence and machine learning enhances data interpretation and reduces turnaround times. Automation in sample preparation and analysis is increasing throughput and reducing human error. Point-of-care molecular diagnostic devices are bringing testing closer to patients, enabling rapid decision-making in clinical settings. These technological advancements are improving the performance of existing tests and encouraging the development of new diagnostic applications. As these technologies evolve and become more accessible, they’re driving growth by expanding the range of conditions that can be diagnosed molecularly and increasing the adoption of molecular diagnostics in various healthcare settings.

Shift toward personalized medicine

The growing emphasis on personalized medicine is a significant driver for the molecular diagnostics market. This approach tailors medical treatment to the individual characteristics of each patient, often based on their genetic profile. Molecular diagnostics is crucial in this paradigm, identifying genetic variations that can inform treatment decisions. In oncology, for example, molecular tests can determine which targeted therapies are most likely effective for a patient’s cancer. Pharmacogenomics, which uses molecular diagnostics to predict drug response based on genetic factors, is increasingly important in optimizing medication selection and dosing. The push for personalized medicine is also driving research into new biomarkers and expanding the applications of molecular diagnostics beyond disease diagnosis to include risk assessment, prognosis, and treatment monitoring. As healthcare continues to move towards more personalized approaches, the demand for molecular diagnostic tests is expected to grow significantly.

United States Molecular Diagnostics Industry Analysis

The leading market players in the United States Molecular Diagnostics market are F Hoffmann-la Roche Ltd, Illumina Ltd, Hologic Corporation, Agilent Technologies Inc., Qiagen NV, Myriad Genetics, Abbott Laboratories, Danaher Corporation, and Becton, Dickinson, and Company.

United States Molecular Diagnostics Company News

In August 2023, QIAGEN received the U.S. FDA approval for the Therascreen PDGFRA RGQ PCR kit. This aids physicians in identifying patients with gastrointestinal stromal tumors (GIST).

In January 2023, the U.S. FDA approved EUA for the VIASURE Monkeypox Virus Real-Time PCR Reagents, which were developed by BD and CerTest Biotec to detect the Mpox virus.

In March 2023, Lucira Health launched the first and only at-home COVID-19 and flu tests. The U.S. FDA gave the COVID-19 & Flu Home Test the first and only Emergency Use Authorization (EUA) for OTC usage at home and other non-laboratory locations.

Related Report:

Global Molecular Diagnostics Market:  https://www.renub.com/global-molecular-diagnostics-market-opportunities-and-future-forecast-414-p.php

Drug Abuse Testing Market:  https://www.renub.com/drugs-abuse-testing-market-p.php

Global Non-Invasive Prenatal Testing Market:  https://www.renub.com/non-invasive-prenatal-testing-market-p.php

Technology – Market is divided into 6 Viewpoints

1. Chips and Microarrays
2. In Situ Hybridization
3. Sequencing
4. Mass Spectrometry (MS)
5. PCR
6. Other Technologies

Application – Market is divided into 6 Viewpoints

1. Pharmacogenomics
2. Infectious Disease
3. Genetic Disease Screening
4. Oncology
5. Blood Screening
6. Microbiology
7. Human Leukocyte Antigen Typing

Product – Market is divided into 3 Viewpoints

1. Instruments
2. Reagents
3. Other Products

End User – Market is divided into 3 Viewpoints

1. Hospitals
2. Laboratories
3. Other End Users

Company Insights:

1. Overviews
2. Recent Development
3. Product Portfolio & Product Launch in Last 1 Year
4. Revenue

Companies Covered:

1. F Hoffmann-la Roche Ltd
2. Illumina Ltd
3. Hologic Corporation
4. Agilent Technologies Inc.
5. Qiagen NV
6. Myriad Genetics
7. Abbott Laboratories
8. Danaher Corporation
9. Becton, Dickinson and Company

About the Company:

Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

Media Contact:

Company Name: Renub Research

Contact Person: Rajat Gupta, Marketing Manager

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Address: 225 Kristie Ln, Roswell, GA 30076

Email: info@renub.com

LinkedIn: https://linkedin.com/company/renub-research

Website: www.renub.com